English
中文繁體
中文简体

Dark
Light

Open Account

US Stock MarketDetailed Quotes

OGN Organon & Co

Watchlist

14.715
+0.205+1.41%

Trading Mar 31 14:07 ET

3.80BMarket Cap4.42P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug
MT NewswiresMar 28 09:33 ET
Express News | European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (Pertuzumab) Biosimilar Candidate Hlx11
ReutersMar 28 06:00 ET
Organon (OGN) Advances While Market Declines: Some Information for Investors
Zacks Mar 18 17:15 ET
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Zhitong FinanceMar 18 03:00 ET
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $24
Moomoo NewsMar 10 04:31 ET · Ratings
Express News | Reported Saturday, Organon's VTAMA Phase 3 Data Shows 84% Of Patients Maintained Mild Disease After 80-Day Off-Treatment Interval In Adults And Children 2+
BenzingaMar 10 03:34 ET

Comments

Teddy123

Mar 28 18:19

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

$Organon & Co (OGN.US)$
Major Win: Organon's Breast Cancer Drug Gets Critical EMA Validation After Trial Success

Daily Investors

Mar 10 20:56

OGN's PDUFA Date: A Potential Catalyst for a Cataclysmic Spike?
Tomorrow is a pivotal day for Organogenesis Holdings Inc. (OGN), a regenerative medicine company focused on wound care, surgical and sports medicine. The company is awaiting a decision from the U.S. Food and Drug Administration (FDA) on its Biologics License Application (BLA) for FortaFlex, a novel treatment for partial-thickness rotator cuff tears. This crucial juncture, known as the PDUFA date (Prescription Drug User Fee Act), cou...

Teddy123

Mar 8 22:59

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Olde

$Organon & Co (OGN.US)$
Can This Skin Treatment Work for Months After Stopping? New Clinical Data Reveals Surprising Results

Jaguar8

Oct 28, 2024 21:26

NEWS

$Organon & Co (OGN.US)$
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global health...

Meltyy

Oct 11, 2024 14:22

🚨 M&A Update! 🚨

Keep an eye on these recently announced & closed M&As: 👀
🟢 Recently Announced:
⇒ $Organon & Co (OGN.US)$ to acquire Dermavant
⇒ $Rafael Holdings (RFL.US)$ to acquire Cyclo Tx
⇒Crown Lab to acquire $Revance Therapeutics(Delisted) (RVNC.US)$
⇒ $Recursion Pharmaceuticals (RXRX.US)$ merger with Exscientia
🔴 Recently Closed:
⇒ $Johnson & Johnson (JNJ.US)$ acquired V-Wave
⇒ Pharmacosmos acquired $GTHX
What companies will be next? 🤔

Market Insights

No. Symbol Price

The9 Ltd

NCTY

15.1150

Mawson Infrastructure

Unlock Now